Invasive candidiasis in the neutropenic cancer patient

Current Fungal Infection Reports

Volumn 5, Issue 1, 2011, Pages 34-41

  Gamaletsou, Maria N ^b   Sipsas, Nikolaos V ^b   Kontoyiannis, Dimitrios P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Antifungal prophylaxis; Antifungal treatment; Cancer; Epidemiology; Invasive candidiasis; Neutropenia

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

BLOOD CULTURE; CANCER PATIENT; CANDIDA; CATHETER REMOVAL; CLINICAL PRACTICE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; EARLY DIAGNOSIS; FUNGUS IDENTIFICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; INVASIVE CANDIDIASIS; MORTALITY; NEUTROPENIA; PROPHYLAXIS; REVIEW; SPECIES DISTRIBUTION; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 79952185902     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-010-0044-4     Document Type: Review

References (55)

1. Shorr AF, Gupta V, Sun X, et al.: Burden of early-onset candidemia: analysis of culture-positive bloodstream infections from a large U.S. database. Crit Care Med 2009, 37:2519-2526.
2. Hidron AI, Edwards JR, Patel J, et al.: Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996-1011.
3. Kao AS, Brandt ME, Pruitt WR, et al.: The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999, 29:1164-1170. (Pubitemid 30265634)
4. Marr KA, Seidel K, White TC, Bowden RA: Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000, 181:309-316. (Pubitemid 30049062)
5. Sipsas NV, Lewis RE, Tarrand J, et al.: Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009, 115:4745-4752. This retrospective study among patients with hematologic malignancies and candidemia showed that the introduction of the new antifungals in the clinical practice for treatment or prophylaxis did not reduce the incidence or mortality of IC in this patient population.
6. Kontoyiannis DP, Marr KA, Park BJ, et al.: Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010, 50:1091-1100.
7. Kami M, Machida U, Okuzumi K, et al.: Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br J Haematol 2002, 117:40-46. (Pubitemid 34304419)
8. Chamilos G, Luna M, Lewis RE, et al.: Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006, 91:986-989.
9. Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991, 164: 731-740.
10. Kontoyiannis DP, Reddy BT, Hanna H, et al.: Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity. Infect Control Hosp Epidemiol 2002, 23:542-545. (Pubitemid 35033867)
11. Tortorano AM, Peman J, Bernhardt H, et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23: 317-322. (Pubitemid 38669942)
12. Hachem R, Hanna H, Kontoyiannis D, et al.: The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008, 112:2493-2499.
13. Nucci M, Anaissie E, Betts RF, et al.: Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010, 51:295-303. Contrary to many previous studies, researchers found that in this cohort of 842 adults with candidemia (only 4.2% of whom were neutropenic), early CVC removal was not associated with any clinical benefit. These findings suggest a re-evaluation of current IDSA treatment recommendations.
14. Wey SB, Mori M, Pfaller MA, et al.: Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988, 148:2642-2645.
15. Horn DL, Neofytos D, Anaissie EJ, et al.: Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009, 48:1695-1703.
16. Slavin MA, Sorrell TC, Marriott D, et al.: Australian Candidemia Study, Australasian Society for Infectious Diseases. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010, 65:1042-1051.
17. Andes DR, Safdar N, Baddley J, et al.: Impact of therapy on mortality across candida spp in patients with invasive candidiasis from randomized clinical trials: a patient level analysis [abstract M-1312]. Presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, USA; September 12-15, 2010.
18. Vehreschild JJ, Rüping MJ, Wisplinghoff H, et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother 2010, 65:1466-1471. The introduction of posaconazole prophylaxis as standard of care for patients with leukemia decreased the incidence of IFIs and the duration of hospitalization but had no effect on crude or attributable mortality.
19. Raad I, Hanna H, Boktour M, et al.: Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 2004, 38:1119-1127. (Pubitemid 38951258)
20. Pappas PG, Kauffman CA, Andes D, et al.: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535. These are updated guidelines for the management of patients with invasive candidiasis, prepared by an Expert Panel of the IDSA.
21. Garey KW, Rege M, Pai MP, et al.: Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43:25-31. (Pubitemid 43939072)
22. Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 2010, 54:184-190.
23. Horvath LL, George BJ, Hospenthal DR: Detection of fifteen species of Candida in an automated blood culture system. J Clin Microbiol 2007, 45:3062-3064. (Pubitemid 47417356)
24. Gherna M, Merz WG: Identification of Candida albicans and Candida glabrata within 1.5 hours directly from positive blood culture bottles with a shortened peptide nucleic acid fluorescence in situ hybridization protocol. J Clin Microbiol 2009, 47:247-248.
25. Sheppard DC, Locas MC, Restieri C, Laverdiere M: Utility of the germ tube test for direct identification of Candida albicans from positive blood culture bottles. J Clin Microbiol 2008, 46:3508-3509.
26. Chen SC, Kontoyiannis DP: New molecular and surrogate biomarker-based tests in the diagnosis of bacterial and fungal infection in febrile neutropenic patients. Curr Opin Infect Dis 2010, 23:567-577.
27. Sendid B, Poirot JL, Tabouret M, et al.: Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 2002, 51:433-442. (Pubitemid 34450601)
28. Lunel FM, Mennink-Kersten MA, Ruegebrink D, et al.: Value of Candida serum markers in patients with invasive candidiasis after myeloablative chemotherapy. Diagn Microbiol Infect Dis 2009, 64:408-415.
29. Verduyn Lunel FM, Donnelly JP, van der Lee HA, et al.: Circulating Candida-specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy. Clin Microbiol Infect 2009, 15:380-386.
30. Ellis M, Al-Ramadi B, Bernsen R, et al.: Prospective evaluation of mannan and anti-mannan antibodies for diagnosis of invasive Candida infections in patients with neutropenic fever. J Med Microbiol 2009, 58:606-615.
31. Senn L, Robinson JO, Schmidt S, et al.: 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008, 46:878-885.
32. Landlinger C, Preuner S, Willinger B, et al.: Species-specific identification of a wide range of clinically relevant fungal pathogens by use of Luminex xMAP technology. J Clin Microbiol 2009, 47:1063-1073.
33. Spiess B, Seifarth W, Hummel M, et al.: DNA microarray-based detection and identification of fungal pathogens in clinical samples from neutropenic patients. J Clin Microbiol 2007, 45:3743-3753. (Pubitemid 350156875)
34. Lau A, Halliday C, Chen SC, et al.: Comparison of whole blood, serum, and plasma for early detection of candidemia by multiplex-tandem PCR. J Clin Microbiol 2010, 48:811-816.
35. Charles PE, Castro C, Ruiz-Santana S, et al.: Serum procalcitonin levels in critically ill patients colonized with Candida spp: new clues for the early recognition of invasive candidiasis? Intensive Care Med 2009, 35:2146-2150.
36. Limper M, de Kruif MD, Duits AJ, et al.: The diagnostic role of procalcitonin and other biomarkers in discriminating infectious from noninfectious fever. J Infect 2010, 60:409-416.
37. Ben-Ami R, Weinberger M, Orni-Wasserlauff R, et al.: Time to blood culture positivity as a marker for catheter-related candidemia. J Clin Microbiol 2008, 46:2222-2226.
38. Marr KA, Seidel K, Slavin MA, et al.: Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000, 96: 2055-2061.
39. Marr KA, Bow E, Chiller T, et al.: Fungal infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009, 44:483-487.
40. Wingard JR, Carter SL, Walsh TJ, et al.: Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection (IFI) after allogeneic hematopoietic cell transplantation (HCT). Blood 2010 Sep 8 (Epub ahead of print). Voriconazole and fluconazole are equally effective as prophylaxis in recipients of allogeneic HCT.
41. Ullmann AJ, Lipton JH, Vesole DH, et al.: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356:335-347. (Pubitemid 46148776)
42. Gergis U, Markey K, Greene J, et al.: Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant 2010, 45:662-667.
43. Cornely OA, Ullmann AJ.: Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death. Clin Infect Dis 2008, 46:1626-1627. (Pubitemid 351706747)
44. Cordonnier C, Pautas C, Maury S, et al.: Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009, 48:1042-1051. The first direct comparison of empiric versus preemptive treatment strategy in neutropenic patients showed that preemptive treatment increased the incidence of invasive fungal disease without increasing mortality, whereas empiric treatment resulted in better survival rates among patients receiving induction chemotherapy.
45. Kubiak DW, Bryar JM, McDonnell AM, et al.: Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. J Infect Dis 2010, 201:1708-1717.
46. Kontoyiannis DP. Echinocandin-based initial therapy in fungemic patients with cancer: a focus on recent guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009, 49:638-639.
47. Sipsas NV, Lewis RE, Raad II, Kontoyiannis DP: Monotherapy with caspofungin for candidemia in adult patients with cancer: a retrospective, single-institution study. Int J Antimicrob Agents 2009, 34:95-98.
48. Betts RF, Nucci M, Talwar D, et al.; Caspofungin High-Dose Study Group: A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009, 48:1676-1684. The study compared standard and high doses of caspofungin in invasive candidiasis and found that both doses are equally safe and well tolerated, thus allowing further studies to see whether higher caspofungin doses offer an efficacy advantage.
49. Colombo AL, Ngai AL, Bourque M, et al.: Caspofungin use in patients with invasive candidiasis caused by common nonalbicans Candida species: review of the caspofungin database. Antimicrob Agents Chemother 2010, 54:1864-1871.
50. Oxman DA, Chow JK, Frendl G, et al.: Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J Antimicrob Chemother 2010, 65:1460-1465.
51. Anaissie EJ, Darouiche RO, Abi-Said D, et al.: Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996, 23:964-972. (Pubitemid 26367478)
52. Mora-Duarte J, Betts R, Rotstein C, et al.; Caspofungin Invasive Candidiasis Study Group: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347:2020-2029. (Pubitemid 35461658)
53. DiNubile MJ, Hille D, Sable CA, Kartsonis NA: Invasive candidiasis in cancer patients: observations from a randomized clinical trial. J Infect 2005, 50:443-449. (Pubitemid 40692031)
54. Pappas PG, Rotstein CM, Betts RF, et al.: Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45:883-893. (Pubitemid 47580382)
55. Kuse ER, Chetchotisakd P, da Cunha CA, et al.;Micafungin Invasive Candidiasis Working Group: Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007, 369:1519-1527. (Pubitemid 46670281)